Xarelto Lawsuits Allege Blood Thinner Causes Internal Hemorrhaging, Including Brain Bleeds, And Fails To Prevent Blood Clots.
Xarelto lawsuits continued to see substantial growth with more than 8,000 combined Xarelto lawsuit claims filed in state and federal courts. The Xarelto lawsuits allege the blood thinner causes gastrointestinal hemorrhage, brain bleeds, blood clots and other side effects that may required hospitalization or a transfusion, and have also caused death. The Xarelto lawsuits also contend that Bayer HealthCare and Johnson & Johnson’s Janssen Pharmaceuticals Inc., Xarelto’s maker and marketer, failed to adequately warn about the blood thinner medication’s safety risks.
“The mounting number of Xarelto lawsuits show that patients are still suffering internal bleeding side effects allegedly after being prescribed the Xarelto blood thinner,” explains Dr. François Blaudeau, attorney and founder of Southern Med Law.
If you’ve been harmed by Xarelto side effects, get help
The Xarelto lawsuit attorneys at Southern Med Law are strong advocates of helping patients who believe they have suffered Xarelto side effects. The firm has spoken with men and women from across the country who experienced serious bleeding events after taking Xarelto. If you or a loved one experienced life-threatening internal bleeding or other complications allegedly associated with Xarelto, please contact the Firm to learn more about your legal rights and to arrange for a free, no obligation Xarelto lawsuit review by calling Southern Med Law today, at 205-547-5525 or visit www.southernmedlaw.com for more information and to fill out a contact form.
Filings of Xarelto lawsuits rise
Filings of federal Xarelto bleeding lawsuits rose from 6,457 to 7,254 from July 15 to August 15, according to the U.S. Judicial Panel on Multidistrict Litigation’s (JPML) docket. The JPML established a multidistrict litigation (MDL) for Xarelto lawsuits in the U.S. District Court, Eastern District of Louisiana. The Xarelto complaints are centralized for coordinated pretrial proceedings. (In Re: Xarelto Products Liability Litigation, No. 2592) In Pennsylvania, a mass tort was established in the Philadelphia Court of Common Pleas to consolidate Xaretlo bleeding claims. Currently, 1,004 Xarelto lawsuits are pending in the mass tort, according to the state court’s Xarelto case list. As filings of Xarelto complaints continue, plaintiffs and defendants in both the state and federal courts are preparing Xarelto cases for bellwether trials. (In Re: Xarelto Litigation, Case ID 150102349)
FDA cautions Xarelto does not have an approved antidote to reverse adverse bleeding events
Xarelto (rivaroxaban) was approved in 2011 by the U.S. Food and Drug Administration (FDA) to prevent deep vein thrombosis and pulmonary embolism after knee or hip replacement surgery. Xarelto was later approved to reduce the risk of stroke and blood clots in patients with atrial fibrillation not caused by a heart valve problem. Xarelto is considered a new generation blood thinner compared to warfarin (Coumadin, Jantoven), a blood thinner that the FDA approved over 50 years ago. Xarelto is more convenient to use because patients do not have to undergo periodic blood tests as do patients taking warfarin. However, the FDA cautions that Xarelto does not have an approved antidote to reverse adverse bleeding events. Warfarin uses vitamin K as a reversal agent for significant bleeding episodes.
[fda.gov/Drugs/NewsEvents/ucm405148.htm, July 17, 2014]
first of four Xarelto bellwether trials scheduled
According to court documents, the first of four Xarelto bellwether trials is scheduled for February 6, 2017 in the Eastern District court in New Orleans. The first case to go trial involves a plaintiff who began taking Xarelto in January 2014 to reduce the risk of stroke due to atrial fibrillation. The complaint alleges that within a matter of weeks, the plaintiff experienced gastrointestinal bleeding as a result of taking Xarelto, According to the Xarelto lawsuit, the plaintiff was hospitalized and had to have several blood transfusions. (Case No. 2:14-cv-02720) The second case is scheduled to go to trial in New Orleans on March 13, 2017. (In Re: Xarelto Products Liability Litigation, No. 2592)
About Southern Med Law And Filing A Xarelto Bleeding Lawsuit
Throughout his career, Dr. Blaudeau has worked hard to develop a strong reputation in healthcare litigation. His first-hand knowledge of medicine has made the Southern Med Law team an aggressive and effective attorney and advocate for those who were harmed due to negligent pharmaceutical companies. If you or a loved one believe they where harmed by Xarelto, please contact Southern Med Law today to learn more about your legal rights. Call today for a free, no obligation Xarelto lawsuit review by filling out our online form, or by calling the office directly at 205-547-5525.
Southern Med Law
François M. Blaudeau, MD JD FACHE FCLM Esquire
2224 1st Avenue North
Birmingham, Alabama 35203